MetaCap

BioVie (BIVI) vs Radiopharm Theranostics (RADX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioVie (BIVI) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 38.2% versus a loss of 86.1%. Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $8.6 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIVI-38.22%RADX-86.15%
+145%+24%-97%
Nov 21, 20251 yearNov 20, 2026
BIVI-97.33%RADX-96.66%
+5%-49%-102%
Dec 2, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIVI versus RADX key metrics
MetricBIVIRADX
Share price$0.80$0.6304
Market cap$8.58M$9.90M
1-day change-12.07%-9.71%
YTD return-31.03%-87.92%
1-year return-38.22%-86.15%
5-year return-99.87%—
EPS (TTM)$-2.85$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.63M
Revenue growth (YoY)—+1114.27%
Net income (latest FY)$-22.07M$-38.34M
Gross margin—1.08%
Operating margin—-1050.63%
Net margin—-1055.27%
52-week high$3.79$16.25
52-week low$0.7515$0.63
Distance from 52-week high-78.89%-96.12%
Analyst consensusnonestrong_buy
Avg. price target upside+557.50%+2595.11%
Average volume568.61K55.23K
Shares outstanding10.72M15.70M
Employees1314
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BIVI has outperformed RADX by 47.9 percentage points over the past year.

About BioVie

BIVI stock →

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Radiopharm Theranostics

RADX stock →

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

BIVI vs RADX FAQ

Which is bigger, BioVie or Radiopharm Theranostics?

Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $8.58M for BioVie (BIVI).

Which stock has performed better over the past year, BIVI or RADX?

BIVI returned -38.22% over the past 12 months, compared with -86.15% for RADX (price return, excluding dividends). Past performance does not predict future results.

Are BioVie and Radiopharm Theranostics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons